en · de · es · fr · pt
aod-9604-notes.peptides6908.com › Wiki › Identity And Research Origin — Explained

Identity And Research Origin — Explained

By Editorial Desk · published 2026-03-24 · last reviewed 2026-05-08 · Wiki

This is a working overview of peptide hormone, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.

Identity and Research Origin

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Research and Regulatory Status

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Aod-9604 at a glance

PropertyValueNotes
Molecular classPeptide fragmentCorresponds to hGH residues 176-191
Common synonymsAOD9604, hGH 176-191Also written as AOD-9604
Typical formLyophilized powderOften supplied in sealed vials
SolubilityWater-solubleDissolves in aqueous buffers
Regulatory statusNot approved as drugBanned in sport; varies by country

Identity and Research Context

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Related pages on this site

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Supporting material

Jerry Andrus (1918–2007) – magician Mike Barrett (born 1968) – TV announcer of the NBA Charles B. Bellinger (1839–1905) – federal district court judge, editor of the State Rights Democrat (now the Albany Democrat-Herald) Charles Burggraf Architect that spent most of his professional career in Albany. Dyrol Burleson 1500 m Olympian George Earle Chamberlain (1854–1928) – 11th Governor of Oregon Daveigh Chase (1990-2026) – actress Abigail Scott Duniway (1834–1915) – writer, newspaper publisher, and women's rights advocate Neil Elshire – former NFL defensive end, Minnesota Vikings Members of Falling Up – Christian rock band Alan L. Hart (1890–1962) – physician and novelist, raised in Albany Glenn L. Jackson (1902-1980) - Businessman and Chairman of the Oregon State Highway Commission Dave Johnson (born 1963) – Olympic athlete and former West Albany High School teacher Percy R. Kelly (1870–1949) – American attorney and jurist in the state of Oregon Ardyth Kennelly (1912–2005) – novelist Frank Morse (born 1943) – politician Sam Shoen (1916–1999) – founder of U-Haul Corp., operated a barbershop in the St. Francis Hotel at First Ave. and Ferry St. while a student at Oregon State College in the early 1940s. Delazon Smith (1816–1860) – politician Elmo Smith (1909–1968) – 27th Governor of Oregon Evelyn Waldren (1908–1986) – aviation pioneer James K. Weatherford (1850–1935) – Speaker of the Oregon House of Representatives (1876) and State Senator Mae Yih (born 1928) – member of the Oregon Legislative Assembly

The Experiment is a 2010 American drama thriller film directed by Paul T. Scheuring and starring Adrien Brody, Forest Whitaker, Cam Gigandet, Clifton Collins Jr., and Maggie Grace, about an experiment which resembles Philip Zimbardo's Stanford prison experiment in 1971. The film is a remake of the 2001 German film Das Experiment, which was directed by Oliver Hirschbiegel.

Badminton stands as one of the most popular and historically significant sports in Hong Kong, governed by the Badminton Association of Hong Kong, China since its establishment in 1934. The sport is designated as a Tier A elite discipline at the Hong Kong Sports Institute, which provides world-class training and scientific support to the national squad. This institutional backing has allowed the city to consistently produce top-tier talent capable of competing at the BWF World Tour and the Olympic Games. The current professional landscape is highlighted by the mixed doubles pairing of Tang Chun-man and Tse Ying-suet, who achieved a career-high world ranking of number two. The duo remains a dominant force on the international circuit, recently securing a historic gold medal at the 2025 Badminton Asia Championships and a podium finish at the 2026 All England Open. In the men's singles discipline, Ng Ka-long Angus has been a mainstay of the global top ten, reaching a peak ranking of number six. He is supported by teammate Lee Cheuk-yiu. This former Hong Kong Open champion has maintained a strong international presence with a career-high ranking of thirteen. On the local front, the sport enjoys immense participation through a robust network of community clubs and school programs. The annual Hong Kong Open, a BWF World Tour Super 500 event is held at the Hong Kong Coliseum.

Beta-thalassemia (β-thalassemia) is an inherited blood disorder, a form of thalassemia resulting in variable outcomes ranging from clinically asymptomatic to severely anemic individuals. It is caused by reduced or absent synthesis of the beta chains of hemoglobin, the molecule that carries oxygen in the blood. Symptoms depend on the extent to which hemoglobin is deficient, and include anemia, pallor, tiredness, enlargement of the spleen, jaundice, and gallstones. In severe cases death ensues. Beta thalassemia occurs due to a mutation of the HBB gene leading to deficient production of the hemoglobin subunit beta-globin; the severity of the disease depends on the nature of the mutation, and whether or not the mutation is homozygous. The body's inability to construct beta-globin leads to reduced or zero production of adult hemoglobin thus causing anemia. The other component of hemoglobin, alpha-globin, accumulates in excess leading to ineffective production of red blood cells, increased hemolysis, and iron overload. Diagnosis is by checking the medical history of near relatives, microscopic examination of blood smear, ferritin test, hemoglobin electrophoresis, and DNA sequencing. As an inherited condition, beta thalassemia cannot be prevented although genetic counselling of potential parents prior to conception can propose the use of donor sperm or eggs. Patients may require repeated blood transfusions throughout life to maintain sufficient hemoglobin levels; this in turn may lead to severe problems associated with iron overload.

== Current research == Since the Human Genome Project developed a blueprint of all human genes in our chromosomes, proteomics researchers have pushed to understand how that blueprint creates life. Diseases and infections are often the result of proteins going wrong, and finding the aberrant one requires sifting through thousands of other proteins. In addition, many problem proteins have not been given names yet or are too rare to find easily. In the last few years, Smith and his team have led work that has reduced analytical steps from hours to minutes. This increased speed has enabled many samples to be processed faster in high-throughput experiments. Smith has led other advances in sensitivity and accuracy that have improved the ability to find rare proteins, bringing proteomics technology to the doorstep of clinical researchers. Smith and collaborators have applied the technology to liver disease and cancer in the hopes of finding rare markers of disease in blood, making diagnosis or treatment safer and faster. In 2007, Scientific American magazine listed Smith and his collaborator Desmond Smith as one of the top 50 researchers for work to understand the origins of Parkinson's disease by mapping where proteins amass in diseased mouse brains. Among other work, Smith and colleagues at PNNL looked at how bacteria and viruses might cause illness. They've learned breast cancer leaves traces in the blood that doctors might research on someday. Smith led early studies for DOE into possible roles for microbes in making biofuels.

Sources: en.wikipedia.org

Notes from published material

A nutrient is a substance used by an organism to survive, grow and reproduce. The requirement for dietary nutrient intake applies to animals, plants, fungi and protists. Nutrients can be incorporated into cells for metabolic purposes or excreted by cells to create non-cellular structures such as hair, scales, feathers, or exoskeletons. Some nutrients can be metabolically converted into smaller molecules in the process of releasing energy such as for carbohydrates, lipids, proteins and fermentation products (ethanol or vinegar) leading to end-products of water and carbon dioxide. All organisms require water. Essential nutrients for animals are the energy sources, some of the amino acids that are combined to create proteins, a subset of fatty acids, vitamins and certain minerals. Plants require more diverse minerals absorbed through roots, plus carbon dioxide and oxygen absorbed through leaves. Fungi live on dead or living organic matter and meet nutrient needs from their host. Different types of organisms have different essential nutrients. Ascorbic acid (vitamin C) is essential to humans and some animal species but most other animals and many plants are able to synthesize it. Nutrients may be organic or inorganic: organic compounds include most compounds containing carbon, while all other chemicals are inorganic. Inorganic nutrients include iron, selenium, and zinc, while organic nutrients include, protein, fats, sugars and vitamins. A classification used primarily to describe nutrient needs of animals divides nutrients into macronutrients and micronutrients.

Similarly to the findings with a strong CYP2D6 inhibitor, a pharmacogenomic clinical study with LSD found that LSD levels were 75% higher in people with non-functional CYP2D6 (poor metabolizers) compared to those with functional CYP2D6. Serotonin syndrome can be caused by combining psychedelics with other serotonergic drugs, including certain antidepressants, opioids, psychostimulants (e.g. MDMA), serotonin 5-HT1 receptor agonists (e.g. triptans), herbs or supplements, and others. However, there is said to be no risk of serotonin syndrome when psychedelics like LSD or psilocybin are taken while on SSRIs. The same is not true of ayahuasca, as ayahuasca also contains harmala alkaloids which act as MAOIs and can produce life-threatening serotonin toxicity when combined with SSRIs. A high rate of seizures has been reported when people on lithium have taken serotonergic psychedelics. In an analysis of online reports, 47% of 62 accounts reported seizures when a psychedelic was taken while on lithium. The mechanism of this interaction is unclear.

In comparison, fetal haptic glucagon receptors are lowered in comparison to adult cells and the glycemic effect of glucagon is blunted. This temporary physiological change aids the increased rate of fetal development during the final trimester. Poorly managed maternal diabetes mellitus is linked to fetal macrosomia, increased risk of miscarriage, and defects in fetal development. Maternal hyperglycemia is also linked to increased insulin levels and beta cell hyperplasia in the post-term infant. Children of diabetic mothers are at an increased risk for conditions such as: polycythemia, renal vein thrombosis, hypocalcemia, respiratory distress syndrome, jaundice, cardiomyopathy, congenital heart disease, and improper organ development.

Angelica keiskei, commonly known under the Japanese name of ashitaba (アシタバ or 明日葉), literally "tomorrow's leaf", is a species of flowering plant in the carrot family. It is native to Japan, where it is found on the Pacific Coast. It is native to the area of the Bōsō Peninsula, Miura Peninsula, Izu Peninsula, and the Izu Islands. It has been widely cultivated outside its natural range.

Austin had guest roles on Celebrity Deathmatch and Seasons 4 and 5 of CBS's Nash Bridges, where he played San Francisco Police Department Inspector Jake Cage. He has appeared on V.I.P and Dilbert. His motion picture debut was in a supporting role as Guard Dunham in the 2005 remake of The Longest Yard. Austin had his first starring film role, as Jack Conrad, a dangerous convict awaiting execution in a Salvadoran prison, who takes part in an illegal deathmatch game that is being broadcast to the public in the 2007 action film The Condemned. In 2010, Austin appeared in The Expendables as Dan Paine, the right-hand man for the primary antagonist of the film James Munroe, played by Eric Roberts, and bodyguard with Gary Daniels who plays The Brit. Shortly after Austin re-teamed with Eric Roberts and Gary Daniels in Hunt to Kill. It was his last American theatrical release film until 2013. Austin appeared as Hugo Panzer on television series Chuck. He has also starred in Damage, The Stranger, Tactical Force, Knockout, Recoil, Maximum Conviction, and The Package. He made an appearance in Grown Ups 2 and his most recent acting role came in Smosh: The Movie. In 2011, a documentary was released about Austin's career titled Stone Cold Steve Austin: The Bottom Line on the Most Popular Superstar of All Time. It included interviews with Austin and his and his rivals while covering his most famous matches, promos, and behind-the-scenes moments.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Is AOD-9604 the same as growth hormone?

No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.

How is AOD-9604 regulated?

Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Network